Research Reports | Market Assessment
April 2016

Gram-Negative Infections | Unmet Need | ESBL | US/EU | 2016

The increasing prevalence and severity of Gram-negative infections (GNIs) caused by extended-spectrum beta-lactamase (ESBL)-producing pathogens have emerged as a global public health concern. Recent surveillance studies find that an increasing proportion of ESBL-producing pathogens are also associated with resistance to other classes of antibiotics, further limiting therapeutic options. As such, new antibiotics with activity against ESBL-producing Gram-negative pathogens represent a key unmet need in the GNI therapy market.

Login to access report
Back to all Market Assessment reports
Login to access report

launch Related Market Assessment Reports